SEC Form 4 · accession 0002141966-26-000002
Cytek Biosciences, Inc. · CTKB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ilan Feuchtwang
Officer — Chief Legal Officer, Secretary
Period of report
Aug 10, 2026
Accepted (ET)
Aug 12, 2026 · 6:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001831915
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 10, 2026 | A | 241,416 | A | — | — | Common Stock | 241,416 | 241,416 | D |
| Employee Stock Option (right to buy)F3 | $4.66 | Aug 10, 2026 | A | 127,118 | A | — | Aug 9, 2036 | Common Stock | 127,118 | 127,118 | D |
Explanation of responses
- F1Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F2The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on August 18, 2027; 3/48 of the RSUs vesting on November 18, 2027 and each November 18 thereafter; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; and 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Invesntive Plan (the "2021 Plan"))).
- F3The shares subject to the option shall vest over 4 years with 25% vesting on August 10, 2027 and 1/48 of the shares vesting each month thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the 2021 Plan)).